First-time generics get US boost (Business Standard India)
Indian pharmaceutical companies led by Ranbaxy Laboratories have bagged 20 first-time generic approvals from the US Food and Drug Administration (FDA) in the eleven months from January to November this year, which constitutes about a quarter of the total 81 approvals given in this period.

Strativa Pharmaceuticals, the Proprietary Products Division of Par Pharmaceutical, Provides an Update on Development ... (Centre Daily Times)
Par Pharmaceutical Companies, Inc. (NYSE: PRX) today provided an update on the development status of its three, in-licensed, proprietary pipeline products: pafuramidine, Loramyc(R) (miconazole Lauriad(R)), and Zensana(TM) (ondansetron). These three products represent the current product pipeline of Strativa Pharmaceuticals, Par's proprietary products division.

Accentia Biopharmaceuticals Reports Fiscal 2007 Year-End Results; Pivotal Phase III Results Pending for SinuNase(TM) ... (Centre Daily Times)
Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that the Company has filed its Annual Report (Form 10-K) with the SEC, reporting the results of its operations for the fiscal year ended September 30, 2007.